Atossa Genetics knallt runter: Bottom Fishing!


Seite 1 von 1
Neuester Beitrag: 25.04.21 00:24
Eröffnet am:07.10.13 16:55von: MilchKaffeeAnzahl Beiträge:9
Neuester Beitrag:25.04.21 00:24von: DanielaaepzaLeser gesamt:11.495
Forum:Hot-Stocks Leser heute:7
Bewertet mit:
2


 

2163 Postings, 4795 Tage MilchKaffeeAtossa Genetics knallt runter: Bottom Fishing!

 
  
    #1
2
07.10.13 16:55
Am Freitag kamen wohl schlechte Nachrichten. Rückruf der ausgelieferten Produkte, neues 510k notwendig.

Hier: http://content.stockpr.com/sec/...-13-054080/0001144204-13-054080.pdf

Es ist davon auszugehen, dass das 510k Ende Oktober gestellt wird + 90 Tage.

Mal sehen, wo der Boden ist und wann man einsteigen kann.  

4701 Postings, 4928 Tage AlibabagoldInteressant

 
  
    #2
09.10.13 13:34
Danke für den Tipp... Droht hier Insolvenz oder kann man mit einem schönen Rebound rechnen?

 

2163 Postings, 4795 Tage MilchKaffeeEin Rückruf...

 
  
    #3
1
09.10.13 14:02
Keine Insolvenz. Die haben Cash. Wenn ich das recht überblicke, ist das ein FDA Geplänkel .. die stellen jetzt den 510k nochmal neu, räumen die Diskrepanzen aus und dann gehts wieder weiter.

"Atossa is removing the ForeCYTE Breast Health Test and the MASCT device from the market to address concerns raised by the FDA in a warning letter received by Atossa in February 2013. The FDA raised concerns about (1) the current instructions for use (IFU); (2) certain promotional claims used to market these devices; and (3) the need for FDA clearance for certain changes made to the Nipple Aspirate Fluid (NAF) specimen collection process identified in the current IFU. Atossa will remove existing product from the market until FDA's concerns are addressed."

Mal sehen, wann sich ein guter Preis bildet, um einzusteigen.  

2074 Postings, 6132 Tage Joschi307Atossa 2,04 $

 
  
    #4
11.10.13 11:23
was ist ein 510k?

http://www.bizjournals.com/seattle/blog/...recalls-breast-health.html

wenn ich das richtig gesehen hab ist das ihr einziges produkt...?!  

1243 Postings, 4401 Tage onkel jameslt. yahoo haben die 0,16 Cent Cash je Aktie.

 
  
    #5
11.10.13 11:30
Damit kommen die noch 1 Q weit....

Nichts für mich, viel zu riskant !  

2163 Postings, 4795 Tage MilchKaffeeNur Papierkram zu erledigen.

 
  
    #6
14.10.13 17:38
Wenn ich das richtig verstehe, handelt es sich nur um Formfehler. Das neue FDA Filing wird es zeigen. Ich gehe davon aus, dass sich hier der PPS im November verdoppelt und bin jetzt mal mit einer relativ kleinen Pos eingestiegen.  

2163 Postings, 4795 Tage MilchKaffeeIch denke die läuft bis 5$ EOY

 
  
    #7
19.11.13 10:20

355 Postings, 3487 Tage ROBS2000Was auch runter geht

 
  
    #8
05.11.14 16:19
geht auch wieder rauf. Aufgrund der eigentlichen guten Kapitalausstattung bin ich mal eingestiegen.  

355 Postings, 3487 Tage ROBS2000News vom 5 Dezember 2014

 
  
    #9
12.12.14 15:16
Atossa Genetics Inc. Announces
Successful Closure of FDA Inspections
SEATTLE, WA -- (Marketwired) -- 12/05/14 -- Atossa Genetics Inc. (NASDAQ: ATOS)
today announced that it has received "establishment inspection reports," or EIRs, from the
U.S. Food and Drug Administration, Office of Compliance, related to inspections conducted
by the FDA in 2012 and 2014. Issuance of the EIRs means that the FDA has now closed
those inspections.
Dr. Steven C. Quay, Chairman, CEO and President, stated, "Over the past 18 months, we
have worked diligently to ensure that all observations noted during the inspections were
being resolved expeditiously. I would like to thank the entire Atossa team for their tireless
commitment to this effort. We will continue to devote significant resources to ensure that
our regulatory compliance meets current standards worldwide with respect to our
business."
About Atossa Genetics
Atossa Genetics Inc. is focused on improving breast health through the development of
laboratory services, medical devices and therapeutics. The laboratory services are being
developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. The
laboratory services and the Company's medical devices are being developed so they can
be used as companions to therapeutics to treat various breast health conditions. For
additional information, please visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release are subject to risks and uncertainties that
may cause actual results to differ materially from the anticipated or estimated future results,
including the risks and uncertainties associated with actions by the FDA, the outcome or
timing of regulatory clearances needed by Atossa to sell its products, responses to
regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls
of products, the efficacy of Atossa's products and services, performance of distributors,
estimated future expenses and cash needs, whether Atossa can launch in the United
States and foreign markets the additional tests, devices and therapeutics in its pipeline in a
timely and cost effective manner, and other risks detailed from time to time in Atossa's
filings with the Securities and Exchange Commission, including without limitation its
periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to
time.
Source: Atossa Genetics Inc  

   Antwort einfügen - nach oben